Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals

Rhea-AI Filing Summary

Bank of America Corporation reports beneficial ownership of 9,962,355 shares (Class A Common Stock) of Ironwood Pharmaceuticals, representing 6.1% of the class. The calculation references 163,058,316 shares outstanding as disclosed in the issuer's Form 10-K as of January 31, 2026. The filing (Schedule 13G/A) was submitted on behalf of Bank of America and certain wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.

Insights

Institutional Ownership Analyst

Large passive holding reported: 9,962,355 shares, 6.1% of Ironwood's Class A stock.

Bank of America Corporation and designated subsidiaries disclose shared voting and dispositive power over 9,962,355 shares. The reporting references an outstanding share base of 163,058,316 as of January 31, 2026, which sets the 6.1% stake.

Whether this stake is passive or strategic is not stated; subsequent filings could show changes. Cash-flow treatment and intent are not specified in the excerpt.

Key Figures

Shares beneficially owned: 9,962,355 shares Percent of class: 6.1% Shares outstanding (as of): 163,058,316 shares

3 metrics

Shares beneficially owned 9,962,355 shares Class A Common Stock reported on Schedule 13G/A

Percent of class 6.1% Calculated using 163,058,316 shares outstanding as of January 31, 2026

Shares outstanding (as of) 163,058,316 shares Reported in issuer's Form 10-K, share totals as of January 31, 2026

Key Terms

beneficially owned, shared dispositive power, Schedule 13G/A

3 terms

beneficially owned regulatory

"Amount beneficially owned: 9,962,355.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 9,962,355.00"

Schedule 13G/A regulatory

"This statement on is being filed by Bank of America Corporation"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 12:59 PM Learn about SEC filing dates

FAQ

What stake does Bank of America hold in Ironwood Pharmaceuticals (IRWD)?

Bank of America beneficially owns 9,962,355 shares, representing 6.1% of Class A Common Stock, per the Schedule 13G/A. The percentage uses an outstanding share base of 163,058,316 disclosed as of January 31, 2026.

Which entities filed the Schedule 13G/A for IRWD on behalf of Bank of America?

The filing was made by Bank of America Corporation on behalf of itself and wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International, per the exhibit statement attached to Item 7.

How is Bank of America's voting and dispositive power described in the filing?

The filing reports 0 shares of sole voting or dispositive power and 9,962,355 shares of shared voting and shared dispositive power, indicating collective authority over the reported shares.

What outstanding share count was used to calculate the 6.1% ownership?

The beneficial ownership calculation relies on 163,058,316 shares outstanding as disclosed in the issuer's Form 10-K, which reports share totals as of January 31, 2026.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

IRONWOOD PHARMACEUTICALS INC

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

46333X108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 46333X108

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,962,355.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,962,355.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,962,355.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 163,058,316 outstanding shares disclosed in the Form 10-K by the issuer on February 26, 2026, which reports share totals as of January 31, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IRONWOOD PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 100 SUMMER STREET, SUITE 2300, 100 SUMMER STREET, SUITE 2300, BOSTON, MASSACHUSETTS, 02110.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 46333X108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 9,962,355.00
(b)	Percent of class: 6.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 9,962,355.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 9,962,355.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	04/27/2026